Low-dose arsenic trioxide sensitizes glucocorticoid-resistant acute lymphoblastic leukemia cells to dexamethasone via an Akt-dependent pathway.

@article{Bornhauser2007LowdoseAT,
  title={Low-dose arsenic trioxide sensitizes glucocorticoid-resistant acute lymphoblastic leukemia cells to dexamethasone via an Akt-dependent pathway.},
  author={Beat C Bornhauser and Laura Bonapace and Dan Lindholm and Rodrigo Mart{\'i}nez and Gunnar Cario and Martin Schrappe and Felix K. Niggli and Beat W. Sch{\"a}fer and Jean-Pierre Bourquin},
  journal={Blood},
  year={2007},
  volume={110 6},
  pages={2084-91}
}
Incorporation of apoptosis-inducing agents into current therapeutic regimens is an attractive strategy to improve treatment for drug-resistant leukemia. We tested the potential of arsenic trioxide (ATO) to restore the response to dexamethasone in glucocorticoid (GC)-resistant acute lymphoblastic leukemia (ALL). Low-dose ATO markedly increased in vitro GC sensitivity of ALL cells from T-cell and precursor B-cell ALL patients with poor in vivo response to prednisone. In GC-resistant cell lines… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 22 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 45 references

Similar Papers

Loading similar papers…